Please enable Javascript
2022 IKCS
In-depth coverage of the 2022 IKCS: NORTH AMERICA
Evaluating Renal Mass Biopsy and Nephrectomy in Small Renal Masses
Robert Dillard
IKCS 2022
|
March 11, 2024
A study evaluated how accurately prospectively collected renal mass biopsy can identify DNA mutations in nephrectomy.
The Gut Microbiome Plays a Role in Metastatic Kidney Cancer
Robert Dillard
IKCS 2022
|
February 1, 2023
Gut bacteria play a role in the development of sarcopenia in metastatic renal cell carcinoma.
Assessing AUA Surveillance Guidelines in Kidney Cancer
Robert Dillard
IKCS 2022
|
February 1, 2023
Following AUA guidelines may increase survival in kidney cancer.
An Algorithm for Differentiating Kidney Cancers
Robert Dillard
IKCS 2022
|
February 1, 2023
An algorithm for assessing solid renal masses called the kidney MR score proved successful in differentiating lesions.
Active Surveillance Is Effective for Small Renal Masses in Patients With ESRD
Robert Dillard
IKCS 2022
|
January 17, 2023
Active surveillance appears effective in renal transplant candidates and immunocompromised patients with small renal mass.
Assessing Treatment Patterns in Patients with Metastatic Kidney Cancer
Robert Dillard
IKCS 2022
|
February 1, 2023
Immune-oncology agents and tyrosine kinase inhibitors are increasingly being used in treating metastatic kidney cancer.
Case Study: Paranasal Sinus Tumor in a Patient With Kidney Cancer
Robert Dillard
IKCS 2022
|
March 10, 2023
Patients presenting with nasal or paranasal sinuses tumors should be checked for metastatic kidney cancer.
Patients With Kidney Cancer Do Better With Exercise
Robert Dillard
IKCS 2022
|
March 10, 2023
Patients with kidney cancer who exercise and stay physically active have better physical and mental health.
AI Can Accurately Predict Cardiotoxicity Risk in Certain Patients With Kidney Cancer
Robert Dillard
IKCS 2022
|
February 1, 2023
Artificial intelligence models can accurately predict cardiotoxicity risk in patients with renal cell carcinoma.
Assessing Risk Factors for End-Stage Renal Disease in Kidney Cancer
Robert Dillard
IKCS 2022
|
March 10, 2023
Patients who undergo treatment for renal cell carcinoma (RCC) have a 10-times greater risk of end-stage renal disease (ESRD).
Cabozantinib and Avelumab Treatment Combination Safe and Effective for Metastatic Kidney Cancer
Robert Dillard
IKCS 2022
|
February 1, 2023
Cabozantinib and avelumab appears safe and effective in patients with metastatic clear cell renal carcinoma.
Patients With Kidney Cancer Treated With Nivolumab Plus Cabozantinib Demonstrate Better Responses
Robert Dillard
IKCS 2022
|
March 10, 2023
Patients with advanced renal cell carcinoma demonstrate better responses on nivolumab plus cabozantinib.
Advertisement
Advertisement
Advertisement
Advertisement